Tag: BAVENCIO
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
How AI-enabled cloud ERP is redefining growth for manufacturing leaders
Manufacturing leaders are entering a new phase of supply chain transformation, where growth is increasingly determined by how quickly and intelligently organisations can respond to change.
